Osteoprotegerin induces cytoskeletal reorganization and activates FAK, Src, and ERK signaling in endothelial cells

European Journal of Haematology

Volumn 85, Issue 1, 2010, Pages 26-35

  Kobayashi Sakamoto, Michiyo ^a   Isogai, Emiko ^a   Holen, Ingunn ^b  

^a HEALTH SCIENCES UNIVERSITY OF HOKKAIDO   (Japan)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Angiogenesis; Cytoskeletal reorganization; Extracellular signal regulated kinase; Osteoprotegerin; Src kinase

Indexed keywords

FOCAL ADHESION KINASE; MATRIGEL; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; OSTEOPROTEGERIN; PROTEIN TYROSINE KINASE;

ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CELL SHAPE; CELL STRUCTURE; CONTROLLED STUDY; CYTOSKELETON; ENDOTHELIUM CELL; ENZYME ACTIVATION; HUMAN; HUMAN CELL; MICROTUBULE; PRIORITY JOURNAL;

CELL PROLIFERATION; CELLS, CULTURED; CYTOSKELETON; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; ENZYME ACTIVATION; FOCAL ADHESION PROTEIN-TYROSINE KINASES; HUMANS; MAP KINASE SIGNALING SYSTEM; MODELS, BIOLOGICAL; NEOVASCULARIZATION, PHYSIOLOGIC; OSTEOPROTEGERIN; PROTEIN KINASE INHIBITORS; RECOMBINANT PROTEINS; RHO-ASSOCIATED KINASES; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES;

EID: 77953868162     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2010.01446.x     Document Type: Article

References (27)

1. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997 89 : 309 319.
2. Yasuda H, Shima N, Nakagawa N, et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 1998 139 : 1329 1337.
3. Reid P, Holen I. Pathophysiological roles of osteoprotegerin (OPG). Eur J Cell Biol 2009 88 : 1 17.
4. Bucay N, Sarosi I, Dunstan CR, et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998 12 : 1260 1268.
5. Jono S, Ikari Y, Shioi A, Mori K, Miki T, Hara K, Nishizawa Y. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation 2002 106 : 1192 1194.
6. Malyankar UM, Scatena M, Suchland KL, Yun TJ, Clark EA, Giachelli CM. Osteoprotegerin is an alpha vbeta 3-induced, NF-kappa B-dependent survival factor for endothelial cells. J Biol Chem 2000 275 : 20959 20962.
7. Cross SS, Yang Z, Brown NJ, et al. Osteoprotegerin (OPG) - a potential new role in the regulation of endothelial cell phenotype and tumor angiogenesis? Int J Cancer 2006 118 : 1901 1908.
8. Bostanci N, Ilgenli T, Emingil G, Afacan B, Han B, Toz H, Atilla G, Hughes FJ, Belibasakis GN. Gingival crevicular fluid levels of RANKL and OPG in periodontal diseases: implications of their relative ratio. J Clin Periodontol 2007 34 : 370 376.
9. Mogi M, Otogoto J, Ota N, Togari A. Differential expression of RANKL and osteoprotegerin in gingival crevicular fluid of patients with periodontitis. J Dent Res 2004 83 : 166 169.
10. Kobayashi-Sakamoto M, Hirose K, Isogai E, Chiba I. NF-kappaB-dependent induction of osteoprotegerin by Porphyromonas gingivalis in endothelial cells. Biochem Biophys Res Commun 2004 315 : 107 112.
11. Kobayashi-Sakamoto M, Hirose K, Nishikata M, Isogai E, Chiba I. Osteoprotegerin protects endothelial cells against apoptotic cell death induced by Porphyromonas gingivalis cysteine proteinases. FEMS Microbiol Lett 2006 264 : 238 245.
12. Kobayashi-Sakamoto M, Isogai E, Hirose K, Chiba I. Role of alphav integrin in osteoprotegerin-induced endothelial cell migration and proliferation. Microvasc Res 2008 76 : 139 144.
13. Zachary I. VEGF signalling: integration and multi-tasking in endothelial cell biology. Biochem Soc Trans 2003 31 (Pt 6 1171 1177.
14. Ruegg C, Mariotti A. Vascular integrins: pleiotropic adhesion and signaling molecules in vascular homeostasis and angiogenesis. Cell Mol Life Sci 2003 60 : 1135 1157.
15. Klemke RL, Cai S, Giannini AL, Gallagher PJ, de Lanerolle P, Cheresh DA. Regulation of cell motility by mitogen-activated protein kinase. J Cell Biol 1997 137 : 481 492.
16. Lamalice L, Le Boeuf F, Huot J. Endothelial cell migration during angiogenesis. Circ Res 2007 100 : 782 794.
17. Palazzo AF, Eng CH, Schlaepfer DD, Marcantonio EE, Gundersen GG. Localized stabilization of microtubules by integrin- and FAK-facilitated Rho signaling. Science 2004 303 : 836 839.
18. Shipman CM, Croucher PI. Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. Cancer Res 2003 63 : 912 916.
19. Moran CS, McCann M, Karan M, Norman P, Ketheesan N, Golledge J. Association of osteoprotegerin with human abdominal aortic aneurysm progression. Circulation 2005 111 : 3119 3125.
20. Kotake S, Udagawa N, Hakoda M, et al. Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients. Arthritis Rheum 2001 44 : 1003 1012.
21. Zauli G, Melloni E, Capitani S, Secchiero P. Role of full-length osteoprotegerin in tumor cell biology. Cell Mol Life Sci 2009 66 : 841 851.
22. Baud'huin M, Duplomb L, Teletchea S, Charrier C, Maillasson M, Fouassier M, Heymann D. Factor VIII-von Willebrand factor complex inhibits osteoclastogenesis and controls cell survival. J Biol Chem 2009 284 : 31704 31713.
23. McGonigle JS, Giachelli CM, Scatena M. Osteoprotegerin and RANKL differentially regulate angiogenesis and endothelial cell function. Angiogenesis 2009 12 : 35 46.
24. Yamaguchi K, Kinosaki M, Goto M, Kobayashi F, Tsuda E, Morinaga T, Higashio K. Characterization of structural domains of human osteoclastogenesis inhibitory factor. J Biol Chem 1998 273 : 5117 5123. (Pubitemid 28108672)
25. Mosheimer BA, Kaneider NC, Feistritzer C, Djanani AM, Sturn DH, Patsch JR, Wiedermann CJ. Syndecan-1 is involved in osteoprotegerin-induced chemotaxis in human peripheral blood monocytes. J Clin Endocrinol Metab 2005 90 : 2964 2971.
26. Derksen PW, Keehnen RM, Evers LM, van Oers MH, Spaargaren M, Pals ST. Cell surface proteoglycan syndecan-1 mediates hepatocyte growth factor binding and promotes Met signaling in multiple myeloma. Blood 2002 99 : 1405 1410.
27. Wilcox-Adelman SA, Denhez F, Goetinck PF. Syndecan-4 modulates focal adhesion kinase phosphorylation. J Biol Chem 2002 277 : 32970 32977.